Abbott Laboratories NYSE:ABT has been making higher highs and lower lows over the last year, potentially signaling a reversal in its downward trend. Monkeypox and the return of cold/flu/COVID season may spark another run to close the price gap on the daily chart around $140. It is currently in a personal buy zone at $110.00. Target #1 = $118.00 Target #2 = $140.00
Do you remember the pandemic period? The markets seemed to crash first, many of us even said, let's keep our money, neither stock market nor investment, let's see the way ahead first, let's not be exposed. Today, they had another case that shook the world. I say they did because I think there is nothing unconsciously done. Does the Monkeypox case look familiar?...
$SIGA followed my chart very precisely and hit my short target💪 I just noticed that $SIGA actually forming a Bump and Run bearish pattern and it could dip even lower to $8-8.60 If it holds above the trendline and volume increases, this pattern may be invalid...
Very interesting level here for SIGA. Not rushing into anything but if we can get this yellow level to hold as support and push higher. Could be a great long term entry. Massive move down with no relief on the way down at all. With a massive level like this it could be a great opportunity for a swing
$SIGA Bearish Rising Wedge formation in the daily TF. It needs a correction to continue this run, it might test the support level at $16-17 then bounce from there. ** I called $SIGA since it was below $11 (check my previous TAs), so if you followed my TA I guess you made a killing profit 💰
$CBIO looks like it has potential to make a large move soon, Also it's #4 in list of top Fintel Gamma Squeeze list📈
Daily closed above major resistance, this might lead it to continue the rally in the coming weeks 🔥
Break above this bull flag will lead the price to reach a new ATH
Just a small idea. I like this company; been trading it since 2018 and the pandemic. "In case" the Monkeypox virus spreads, this could be a decent hedge. We saw $SIGA with huge gaps last week (similar play), which likely will open higher on Monday. According to one source; It's spread through droplets and/or contact with infected lesions; skin contact coughs,...
For the longest time, I have been debating whether or not to begin posting my trading sentiments since the trading community I look after & am a part of is a very private one. That said. we are in unprecedented times, a lot of people do not know what is coming their way. nevermind how to protect themselves/ take advantage of relevant opportunities. So I have...
Nice breakout from that bullish pennant flag🔥 Monkeypox might be the next Pandemic (according to WHO) and $SIGA might be the next $MRNA (5000% up since the beginning of Covid)🚀📈
NovaBay Pharmaceuticals, Inc. (NBY) owns Avenova, which is EPA listed as an effective disinfectant for monkeypox. On 5/20/2022 Ascendiant Capital Markets brokerage set a price target of $4.00 for NovaBay Pharmaceuticals, Inc. (NBY). The stock is now only 0.20usd. Before the pandemic news, on their last earnings, they mentioned that Avenova Spray unit sales...
Hype and sentiment regarding a monkeypox outbreak has been the only driver in SIGAs price, apart from minor PR. Volume will slowly wither away, and investors will begin to take profits. It will not remain at this price range for much longer. Looks to be an easy short/put. Will be opening 10$ Puts with a June 17th expiry.
Bavarian Nordic is the only company with an FDA approved Monkey Pox Vaccine Bavarian Nordic A/S develops, manufactures, and commercializes life-saving vaccines. The company offers non-replicating smallpox and monkeypox vaccines under the IMVAMUNE, IMVANEX, and JYNNEOS names; rabies vaccine for human use under the Rabipur/RabAvert name; tick-borne encephalitis...
New York-based pharmaceutical firm SIGA Technologies (NASDAQ:SIGA) is among the companies to benefit from the growing threat of monkeypox, recently pushing its shares to an almost decade-high after the company obtained approval in Europe to use its TPOXX antiviral drug for the treatment of monkeypox. Smallpox jabs vs monkeypox On May 19, the World Health...
Tonix is a producer of the TNX-801 vaccine, effective against Smallpox and Monkeypox. But that`s not all! They have a strong balance sheet, Cash and Cash Equivalents Totaled Approximately $140 Million VS its mk cap of only $44.03Mil. Seth Lederman, M.D., Chief Executive Officer of Tonix: “Tonix is making meaningful strides developing our rich portfolio of high...
We have here a company that acquires value with the pandemic, now everybody is using Zoom to make video conferences, you can see the balance sheet improvement, the price is slightly high form the IPO price. If the monkey pox progress, this stock will go back to the $400 level.
With the small rise of pox news going on in the U.S., be it the second case of monkeypox this year , to smallpox vials found at a vaccine research facility in Pennsylvania, it brings to question as to whether or not health companies that have the capability to manufacture vaccines, treatments, and test kits against smallpox will be the new growth sector of...